DZD8586
Phase 2Small molecule
DZD8586 is one of 145 small molecule programs targeting Lymphoma. It is currently in Phase 2.
5
Indications
9
Total Trials
6
Active Trials
144
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1DZD8586
DDizal Pharmaceuticals
Phase 2
Blenoxane
SSequus Pharmaceuticals
Preclinical
Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
PEG-Intron
Merck & Co.Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immune Thrombocytopenia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DZD8586. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDizal Pharmaceuticals